BiotechTube
Aggredyne

Aggredyne

Houston, United States· Est.
aggredyne.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

AggreDyne is a growth-stage, private diagnostic company founded in 2011 and headquartered in Houston, Texas. Its core offering is the AggreGuide A-100 system, a simple, reliable, low-cost instrument for on-demand platelet function testing (PFT) to monitor patient response to antiplatelet therapy. The company has achieved regulatory clearance in the US and EU and is targeting a significant market opportunity in cardiovascular and other therapeutic areas where antiplatelet drugs are used. Leadership includes experienced executives and advisors with backgrounds in finance, engineering, and medicine.

CardiovascularNeurology

Technology Platform

Patented light scattering technology for measuring platelet aggregation and function in a benchtop diagnostic system (AggreGuide A-100).

Opportunities

The large and growing population on antiplatelet therapy creates a significant addressable market for personalized monitoring.
The trend towards point-of-care testing and value-based care supports the adoption of rapid, actionable diagnostic tools like the A-100.
The company's low-cost, simple system positions it well for adoption in cost-conscious settings like physician office laboratories.

Risk Factors

Intense competition from larger, established diagnostic companies with broader portfolios and greater sales resources.
Reimbursement challenges and lack of universal clinical guidelines for routine platelet function testing may limit adoption.
As a small, private company with a single product platform, it faces execution and funding risks.

Competitive Landscape

AggreDyne competes in the platelet function testing market against companies like Werfen (formerly Instrumentation Laboratory, with the PFA-200), Roche (with the Multiplate analyzer), and Abbott (with the now-discontinued VerifyNow system). Competition is based on assay methodology, ease of use, cost, speed, clinical data, and integration into laboratory workflows.

More companies in Diagnostics & Precision Medicine →More companies in United States →